Milestone Pharmaceuticals Inc.(MIST)

$1.15—

Chart

Milestone Pharmaceuticals Inc.(MIST)

NASDAQ

$1.15—

Chart Studio

MIST(MIST)

MIST

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.20

Nov 11, 2026 · Reports before open

Revenue Estimate

$1M

FY2029E EPS$0.06

FY2030E EPS$0.37

Analyst Sentiment

Wall St. Consensus

Buy

7 analysts·Limited coverage

Score

6 Buy (86%)1 Hold (14%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

686%

Hold

114%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

+162.0%

Consensus

$4.50

+293.0%

Bull

$6.00

+424.0%

12-Month Target Range7 analysts

$3.00$4.50$6.00

Current $1.15Consensus

Current Price

$1.15

Upside to Consensus

$3.35

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+478.29%

EPS—

FY2028

Rev+375.48%

EPS—

FY2029

Rev+76.21%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$22M	$105M	$185M	$262M
Low	$3M	$20M	$76M	$135M	$190M
High	$5M	$26M	$141M	$248M	$350M
EBITDA Avg	$-2M	$-13M	$-63M	$-111M	$-157M
Low	$-3M	$-16M	$-85M	$-149M	$-210M
High	$-2M	$-12M	$-46M	$-81M	$-114M
EBIT Avg	$-2M	$-13M	$-63M	$-111M	$-157M
Low	$-3M	$-16M	$-85M	$-149M	$-210M
High	$-2M	$-12M	$-46M	$-81M	$-114M
Net Income Avg	$-71M	$-70M	$-26M	$5M	$31M
Low	$-76M	$-87M	$-38M	$3M	$20M
High	$-65M	$-49M	$-17M	$7M	$45M
EPS Avg	$-0.84	$-0.84	$-0.31	$0.06	$0.37
Low	$-0.90	$-1.04	$-0.45	$0.04	$0.24
High	$-0.77	$-0.59	$-0.20	$0.08	$0.54
Analysts (Rev / EPS)	5 / 5	5 / 5	1 / 2	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$1M	$2M	$3M	$4M	$6M	$9M
Low	$699,708	$2M	$2M	$3M	$4M	$5M
High	$2M	$2M	$4M	$5M	$8M	$11M
EBITDA Avg	$-685,714	$-1M	$-2M	$-2M	$-4M	$-5M
Low	$-932,944	$-1M	$-2M	$-3M	$-5M	$-7M
High	$-419,824	$-946,310	$-1M	$-2M	$-2M	$-3M
EBIT Avg	$-685,714	$-1M	$-2M	$-2M	$-4M	$-5M
Low	$-932,944	$-1M	$-2M	$-3M	$-5M	$-7M
High	$-419,824	$-946,310	$-1M	$-2M	$-2M	$-3M
Net Income Avg	$-30M	$-32M	$-32M	$-32M	$-32M	$-31M
Low	$-33M	$-33M	$-44M	$-45M	$-45M	$-43M
High	$-24M	$-29M	$-16M	$-16M	$-16M	$-15M
EPS Avg	$-0.22	$-0.23	$-0.23	$-0.23	$-0.23	$-0.23
Low	$-0.24	$-0.24	$-0.32	$-0.32	$-0.32	$-0.31
High	$-0.17	$-0.21	$-0.11	$-0.11	$-0.12	$-0.11
Analysts (Rev / EPS)	4 / 4	5 / 4	4 / 1	4 / 1	4 / 1	4 / 1

Earnings Surprises

Recent Analyst Actions

Aug 20, 2026Cantor Fitzgerald

Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald

Target:$3.00

+177.8%from $1.08

Apr 10, 2026Raymond James

Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James

Target:$6.00

+193.5%from $2.04

Dec 16, 2025Wells Fargo

Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo

Target:$8.00

+241.9%from $2.34

Dec 15, 2025H.C. Wainwright

Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright

Target:$8.00

+210.7%from $2.58

Apr 22, 2022Piper Sandler

Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10

Target:$10.00

+39.9%from $7.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance